Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
recMAGE-A3 adjuvant immunotherapy after cystectomy in MAGE-A3-positive muscle-invasive bladder cancer
NL-OMON28470Suspended
- Sponsor
- EAU Research Foundation
- Start
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial in bladder cancer comparing recMAGE-A3 + AS15 with placebo (2 arms). Primary endpoint: Disease-free survival. Started Jun 2011; status: suspended.
02
Drugs
astuprotimut-RAS15
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NL-OMON28470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28470.